Get started
Intra-Cellular Therapies Inc.Intra-Cellular Therapies Inc.Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

ITCI chart

Key stats

Market capitalization
‪7.02 B‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.46USD
Net income
‪−139.67 M‬USD
Revenue
‪464.37 M‬USD
Shares float
‪94.22 M‬
Beta (1Y)
1.35

About Intra-Cellular Therapies Inc.

Sector
Health Technology
CEO
Sharon L. Mates
Headquarters
New York
Website
intracellulartherapies.com
Employees (FY)
610
Founded
2002
ISIN
US46116X1019
FIGI
BBG0026ZFZC4
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ITCI is 72.37 USD — it has increased by 0.51% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Intra-Cellular Therapies Inc. stocks are traded under the ticker ITCI.
Intra-Cellular Therapies Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
ITCI stock is 5.12% volatile and has beta coefficient of 1.35. Check out the list of the most volatile stocks — is Intra-Cellular Therapies Inc. there?
One year price forecast for Intra-Cellular Therapies Inc. has a max estimate of 120.00 USD and a min estimate of 65.00 USD.
ITCI earnings for the last quarter are −0.25 USD per share, whereas the estimation was −0.57 USD resulting in a 55.78% surprise. The estimated earnings for the next quarter are −0.45 USD per share. See more details about Intra-Cellular Therapies Inc. earnings.
Intra-Cellular Therapies Inc. revenue for the last quarter amounts to ‪126.17 M‬ USD despite the estimated figure of ‪119.25 M‬ USD. In the next quarter revenue is expected to reach ‪135.68 M‬ USD.
Yes, you can track Intra-Cellular Therapies Inc. financials in yearly and quarterly reports right on TradingView.
ITCI stock has risen by 6.36% compared to the previous week, the month change is a 10.49% rise, over the last year Intra-Cellular Therapies Inc. has showed a 15.74% increase.
ITCI net income for the last quarter is ‪−28.58 M‬ USD, while the quarter before that showed ‪−24.26 M‬ USD of net income which accounts for −17.81% change. Track more Intra-Cellular Therapies Inc. financial stats to get the full picture.
Today Intra-Cellular Therapies Inc. has the market capitalization of ‪7.02 B‬, it has increased by 1.54% over the last week.
No, ITCI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ITCI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Intra-Cellular Therapies Inc. stock right from TradingView charts — choose your broker and connect to your account.
ITCI reached its all-time high on Feb 16, 2024 with the price of 76.11 USD, and its all-time low was 6.75 USD and was reached on Oct 1, 2019.
See other stocks reaching their highest and lowest prices.
As of Apr 20, 2024, the company has 610.00 employees. See our rating of the largest employees — is Intra-Cellular Therapies Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Intra-Cellular Therapies Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Intra-Cellular Therapies Inc. stock shows the buy signal. See more of Intra-Cellular Therapies Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Intra-Cellular Therapies Inc. future price: according to them, ITCI price has a max estimate of 120.00 USD and a min estimate of 65.00 USD. Read a more detailed Intra-Cellular Therapies Inc. forecast: see what analysts think of Intra-Cellular Therapies Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Intra-Cellular Therapies Inc. EBITDA is ‪−158.85 M‬ USD, and current EBITDA margin is −34.21%. See more stats in Intra-Cellular Therapies Inc. financial statements.